[New data presented at ASCO 2002 concerning small cell bronchial cancer].
Smit
E-F
EF
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D010879:Piperazines / Q000008:administration & dosage; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage; D015363:Quinolones / Q000008:administration & dosage; D012907:Smoking / Q000009:adverse effects; D000074606:Smoking Prevention; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D015363:Quinolones; D003841:Deoxycytidine; D005047:Etoposide; D000068877:Imatinib Mesylate; D016190:Carboplatin; C402769:tipifarnib; D002945:Cisplatin; D000093542:Gemcitabine